Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | CA2 | P00918 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | PKLR | P30613 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30986771 | 1.00 | CA1 (0.39) | CA1CA2CA12CA7CA13 | |
| SCHEMBL31454807 | 0.84 | PKM (0.35) | CA1CA2CA12CA7CA13 | |
| SCHEMBL22146034 | 0.82 | PTGS2 (0.34) | CA1CA2CA12CA7CA13 | |
| SCHEMBL7334530 | 0.78 | PKM (0.39) | CA1CA2CA7CES2CES1 | |
| SCHEMBL22145990 | 0.78 | TRPV4 (0.43) | PKMALDH1A1PTGS2PTGS1 | |
| SCHEMBL3528750 | 0.78 | CES2 (0.39) | CES2CES1ALDH1A1HSD17B10 | |
| SCHEMBL532887 | 0.77 | PKM (0.50) | CES2CES1PKMPKLRALDH1A1 | |
| SCHEMBL4502132 | 0.77 | CA1 (0.58) | CA1CA2CA12CA7CA13 | |
| SCHEMBL29141548 | 0.77 | CA1 (0.41) | CA1CA2CA12CA7CA13 | |
| SCHEMBL8412750 | 0.76 | PKM (0.32) | PKMPKLRALDH1A1HSD17B10TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115687-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORP USA (US) | 2025-04-10 | — | — | US | disclosed |
| WO-2025075722-A1 | PRODUCTION METHOD FOR SOLID CATALYST COMPONENT FOR POLYMERIZING OLEFINS, AND CATALYST FOR POLYMERIZAING OLEFINS | FORMOSA PLASTICS CORPORATION, U.S.A. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-118344270-A | Fluorine-containing diphenyl sulfone acaricide and preparation method thereof | 柳州市惠农化工有限公司 | 2024-07-16 | — | — | CN | disclosed |
| EP-3939979-A1 | JAK KINASE INHIBITOR, PREPARATION METHOD FOR SAME, AND APPLICATIONS THEREOF IN FIELD OF MEDICINE | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-01-19 | — | — | EP | disclosed |
| CN-108698982-B | Fluorine atom-containing compound and use thereof | 日产化学工业株式会社 | 2021-07-16 | — | — | CN | disclosed |
| EP-3404017-B1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL IND LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-07-02 | — | — | US | disclosed |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-01-31 | — | — | US | disclosed |
| EP-3404017-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | Nissan Chemical Industries, Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| EP-1789041-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. | 2006-02-02 | — | — | US | disclosed |
| WO-2006010546-A2 | ARYL-PYRIDINE DERIVATIVES AS 11-BETA-HSD1 INHIBITORS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-02-02 | — | — | WO | disclosed |
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR (US) | 2006-01-05 | — | — | US | disclosed |
| US-6958352-B2 | Compounds for inhibiting insulin secretion and methods related thereto | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1472214-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SmithKline Beecham Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | MITOKOR | 2004-03-04 | — | — | US | disclosed |
| WO-2003066035-A2 | COMPOUNDS FOR INHIBITING INSULIN SECRETION AND METHODS RELATED THERETO | SMITHKLINE BEECHAM CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| US-5811439-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION; ANTILEPEMIC AGENTS | SENGA PHARMACEUTICAL LABORATORY INC. (JP) | 1998-09-22 | — | — | US | disclosed |
| EP-0780389-A1 | Thiazolidinedione derivatives, process for their preparation and pharmaceutical compositions containing them | TOBISHI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336686-B2 | Fluorine atom-containing compound and use thereof | ARF1, ARF5, ARFGAP1 | CA1 1335/4885CA2 2792/4885CA12 2173/4885 |
| US-20190031600-A1 | FLUORINE ATOM-CONTAINING COMPOUND AND USE THEREOF | ARF1, ARF5, ARFGAP1 | CA1 1335/4885CA2 2792/4885CA12 2173/4885 |
| US-20060004062-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, INSR | CA1 527/4885CA2 892/4885CA12 2293/4885 |
| US-20040044049-A1 | Compounds for inhibiting insulin secretion and methods related thereto | IAPP, GPR119, IRS1 | CA1 728/4885CA2 1053/4885CA12 3046/4885 |
| US-20060025455-A1 | New 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes | GPR119, CYP4B1, SLC5A1 | CA1 4380/4885CA2 2590/4885CA12 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.